Form 4: Scholar Rock Director Katie Peng Boosts Equity Holdings with New Stock and Option Grants

Scholar Rock Holding Corp. Director Katie Peng has increased her beneficial ownership in the company through the acquisition of restricted stock units and stock options, as detailed in a recent SEC Form 4 filing.

Summary

• Katie Peng, a Director of Scholar Rock Holding Corp. (SRRK), acquired 7,632 restricted stock units (RSUs) and 9,206 stock options on May 22, 2025.
• The RSUs represent the contingent right to receive one share of common stock upon vesting, with a reported acquisition price of $0.
• The stock options have an exercise price of $30.46 per share and were acquired at a reported price of $0.
• Following these transactions, Ms. Peng beneficially owns 37,951 shares of common stock, which includes 14,671 direct shares and 23,280 RSUs.
• She also beneficially owns 9,206 stock options.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director is generally viewed positively as it aligns their interests with shareholders and indicates confidence in the company's future. This is a routine compensation event.

Positives

• Director Katie Peng increased her equity stake in Scholar Rock Holding Corp. through the acquisition of 7,632 restricted stock units and 9,206 stock options.
• The acquisition of equity by a director typically signals alignment of interests with shareholders and confidence in the company's future performance.

Negatives

• No negative information is presented in this Form 4 filing.

Risks

• The vesting of the acquired restricted stock units and stock options is subject to Katie Peng's continued service to the Issuer through the specified vesting dates.

Future Outlook

The vesting schedules for the acquired restricted stock units and stock options indicate that Katie Peng's full beneficial ownership of these new grants is contingent upon her continued service to Scholar Rock Holding Corp. until at least June 15, 2026, or the date of the next Annual Meeting for RSUs, and the first anniversary of the grant date or the next Annual Meeting for options.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director. Such grants are common compensation practices in the biotechnology and pharmaceutical industries, aiming to align the interests of directors and executives with long-term shareholder value.

Comparison to Industry Standards

• Equity grants to directors, including restricted stock units and stock options, are standard compensation components across publicly traded companies, particularly in the biotech sector.
• The specific amounts and vesting schedules are typically determined by the company's compensation committee based on market benchmarks for director compensation, company performance, and individual contributions. Without specific compensation committee reports or peer group data, a direct comparison to specific comparable companies like Biogen Inc., Sarepta Therapeutics, or Alnylam Pharmaceuticals is not possible from this document alone, but the mechanism of compensation is consistent with industry norms.

Stakeholder Impact

• Shareholders: Positive, as the director's increased equity stake aligns her financial interests with those of the shareholders, potentially incentivizing long-term value creation.

Next Steps

• Vesting of 7,632 restricted stock units on the earlier of June 15, 2026, or the date of the Issuer's next Annual Meeting, subject to continued service.
• Vesting of 9,206 stock options on the earlier of the first anniversary following the date of grant (May 22, 2026) or the date of the Issuer's next Annual Meeting, subject to continued service.

Key Dates

Keywords

Scholar Rock Holding Corp, SRRK, Form 4, insider transaction, director compensation, equity grant, restricted stock units, stock options, beneficial ownership